Home  /  Resource Library  /  An open-label, phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma

An open-label, phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma

Results of a phase II study investigating Entospletinib for relapsed DLBCL.